Article in American journal of physiology. Cell physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Christopher J GuerrieroDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.ORCID 0000-0002-1046-2300
Marcelo D CarattinoDepartments of Medicine and Cell Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.ORCID 0000-0003-1901-1618
Katherine G SharpDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.
Luke J KantzDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.
Nikolay P GreskoDepartment of Cellular and Molecular Physiology, Yale University, New Haven, Connecticut, United States.
Michael J CaplanDepartment of Cellular and Molecular Physiology, Yale University, New Haven, Connecticut, United States.ORCID 0000-0001-5768-4405
Jeffrey L BrodskyDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.ORCID 0000-0002-6984-8486
Funding
Single Nephron and MetabolomicsP30DK079307 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CARATTINO, MARCELO DANIEL · 2008 to 2022
$13.4M
National Coordinating Center (NCC) for the Polycystic Kidney Disease (PKD) Research and Translation Core CentersU24DK126110 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI Terry J Watnick · 2020 to 2026
$7.4M
PKD Innovation and Resource Development CoreU54DK126114 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI Feng Qian · 2020 to 2026
$7.3M
Resource Development CoreU54DK137329 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Thomas R Kleyman · 2023 to 2026
$4.8M
Modulating Hsp70-dependent proteostasis in Alzheimer's DiseaseR35GM131732 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JEFFREY L. BRODSKY · 2019 to 2026
$3.4M
Role of PIEZO Channels in Bladder Function and DysfunctionR01DK119183 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI APODACA, GERARD L, CARATTINO, MARCELO DANIEL · 2019 to 2023
$3.0M
Role of acid-sensing ion channels in bladder sensory signalingR01DK134431 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CARATTINO, MARCELO DANIEL · 2023 to 2025
$941k
Proteostatic regulation of disease-causing polycystin 2 variantsR03DK124659 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GUERRIERO, CHRISTOPHER JAMES · 2020 to 2021
$235k
Developing a new platform to characterize and treat disease-associated polycystin variantsR21DK137149 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GUERRIERO, CHRISTOPHER JAMES · 2023 to 2023
$199k
HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK079307HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK119183HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK124659HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK125034HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK134431HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK137149HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DK137329HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) U24DK126110HHS | NIH | National Institute of General Medical Sciences (NIGMS) 131732NIDDK NIH HHS P30 DK079307NIDDK NIH HHS R01 DK119183NIDDK NIH HHS R01 DK134431NIDDK NIH HHS R03 DK124659NIDDK NIH HHS R21 DK137149NIDDK NIH HHS U54 DK126114NIDDK NIH HHS U54 DK137329NIGMS NIH HHS R35 GM131732NSF | National Science Foundation Graduate Research Fellowship Program (GRFP) 2139321U.S. Department of Defense (DOD) PR191158
6 · The paper itself
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disorder leading to end-stage renal disease. ADPKD arises from mutations in the
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Identification of polycystin 2 missense mutants targeted for endoplasmic reticulum-associated degradation. · full record | OpenQuestion